The companys lead therapy AIO 001 is designed to block TSLP a protein linked to inflammation in AstraZenecas approved medicine Tezspire . Aiolos says its experimental treatment has unique properties that allow for a significantly extended halflife. The company plans to advance AIO001 into a Phase 2 trial for patients with moderatetosevere asthma after promising early results